BidaskClub downgraded shares of BioTelemetry (NASDAQ:BEAT) from a buy rating to a hold rating in a research note released on Friday.

Several other analysts have also recently commented on BEAT. SunTrust Banks initiated coverage on shares of BioTelemetry in a research note on Monday, October 23rd. They set a buy rating and a $41.00 price target on the stock. Raymond James Financial started coverage on shares of BioTelemetry in a research note on Thursday, October 26th. They set an outperform rating and a $37.00 price target on the stock. Zacks Investment Research lowered shares of BioTelemetry from a hold rating to a strong sell rating in a report on Thursday, November 2nd. Finally, Dougherty & Co restated a buy rating and issued a $40.00 price objective on shares of BioTelemetry in a report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average price target of $42.86.

BioTelemetry (NASDAQ:BEAT) traded down $1.95 on Friday, hitting $31.20. 504,897 shares of the stock traded hands, compared to its average volume of 460,567. BioTelemetry has a twelve month low of $23.30 and a twelve month high of $39.20. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.60 and a quick ratio of 1.48. The company has a market capitalization of $1,070.00, a PE ratio of 23.82, a P/E/G ratio of 1.47 and a beta of 0.67.

BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings results on Tuesday, November 7th. The medical research company reported $0.16 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.25 by ($0.09). BioTelemetry had a net margin of 16.10% and a return on equity of 13.66%. The company had revenue of $81.02 million for the quarter, compared to the consensus estimate of $82.10 million. During the same period last year, the company earned $0.21 earnings per share. BioTelemetry’s revenue for the quarter was up 52.7% compared to the same quarter last year. sell-side analysts anticipate that BioTelemetry will post 0.83 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Winslow Evans & Crocker Inc. acquired a new position in BioTelemetry in the third quarter valued at approximately $109,000. Pinebridge Investments L.P. lifted its holdings in BioTelemetry by 2.0% in the second quarter. Pinebridge Investments L.P. now owns 3,775 shares of the medical research company’s stock valued at $126,000 after buying an additional 75 shares during the period. Piedmont Investment Advisors LLC acquired a new position in BioTelemetry in the second quarter valued at approximately $207,000. UBS Asset Management Americas Inc. acquired a new position in BioTelemetry in the second quarter valued at approximately $208,000. Finally, Raymond James Financial Services Advisors Inc. acquired a new position in BioTelemetry in the second quarter valued at approximately $212,000. Institutional investors and hedge funds own 84.07% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “BioTelemetry (BEAT) Cut to “Hold” at BidaskClub” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.watchlistnews.com/biotelemetry-beat-cut-to-hold-at-bidaskclub/1842278.html.

About BioTelemetry

BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.

Analyst Recommendations for BioTelemetry (NASDAQ:BEAT)

Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.